前哨淋巴結標記於子宮內膜癌應用與未來

Application and future of sentinel lymph node mapping in endometrial cancer

目前針對子宮內膜癌的治療準以分期手術治療為主，並依結果決定後續治療方針。然標準手術中的雙側骨盆切淋巴結切除，可能會有延長手術時間、傷及神經或血管等可能，術後也可能會有下肢淋巴水腫的問題，影響病人的生活品質。目前NCCN和ESMO都各自將其寫入臨床指引，可作為早期子宮內膜癌患者的系統性雙側淋巴結切除之替代方案。本篇回顧近期幾篇文獻，了解關於前哨淋巴結標記的應用、目前相關研究和未來發展可能。

Currently, the mainstay treatment for endometrial cancer involves staging surgery, with subsequent treatment decisions based on the results. However, standard surgery involving bilateral pelvic lymph node dissection may prolong operation times, pose risks to nerves or blood vessels, and lead to postoperative lower limb lymphedema, impacting patients' quality of life. Both NCCN and ESMO have incorporated alternatives to systematic bilateral lymph node dissection into their clinical guidelines for early-stage endometrial cancer patients. This review examines recent literature on the application of sentinel lymph node mapping, current research findings, and future potential developments in this area.